news about weight loss and In early February this year, on her YouTube channel “The Hangry Woman,” Mila Clarke Buckley shared her positive experiences taking Ozempic, an antidiabetic medication taken via weekly subcutaneous injection that was first approved by the Food and Drug Administration in 2017.
After two months on it, she recounted, her too-high average blood sugar level (the defining characteristic of diabetes) had steadily declined, her constant and intrusive cravings for food had gone away, and she began to lose weight consistently.
But she also, like many users, experienced a week or so long bout of gastrointestinal symptoms like nausea and constipation once she moved up to a slightly higher dose, which was almost enough to make her stop taking the drug. Buckley stuck through the initial turbulence, though, and in a six-month update video, she called it a wonder drugthat finally helped her lower her blood sugar—a years-long frustration that she had discussed in earlier videos.
In the comments of both her videos were curious onlookers and Ozempic users who backed up her claims of newfound success in managing their diabetes and losing weight.
“After I started taking it, it was almost immediate. I dropped like eight pounds within two months doing nothing differently. So for me, this was awesome, because I’ve always had trouble with this,” Buckley, an author, speaker, and blogger who largely talks about her experiences with diabetes on her channel, told Gizmodo over the phone. “But it’s really interesting that it’s working in this way.
Both for weight loss, which is always something that I wanted for myself—my doctor’s never said that I have to lose weight—and then to also have it be something that was helping with my diabetes management.”
Buckley’s review would soon be relevant to an even greater number of people than the 34 million Americans currently thought to have diabetes.
Days after her latest video, Ozempic’s makers, Novo Nordisk, obtained approval from the Food and Drug Administration to sell a new, higher dose version of the drug called Wegovy—one explicitly meant to help people with obesity, long since (and more controversially as of late) defined as having a body mass index over 30, lose weight.